Mild liver enzyme abnormalities: Eliminating hemochromatosis as cause

Clinical Chemistry

Volumn 43, Issue 8 SUPPL., 1997, Pages 1535-1538

  Witte, David L ^a  

^a Laboratory Control Ltd   (United States)

Author keywords

Ferritin; Hemochromatosis; HLA H; Iron metabolism; Iron binding capacity; Screening

Indexed keywords

FERRITIN; HLA ANTIGEN; LIVER ENZYME;

ALGORITHM; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GENETIC SCREENING; HEMOCHROMATOSIS; HUMAN; IRON BINDING CAPACITY; IRON METABOLISM; LIVER METABOLISM;

EID: 0030792345     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.8.1535     Document Type: Conference Paper

References (26)

1. Hulterantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21:109-13.
2. VanNess MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-8.
3. Hulterantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J Intern Med 1993;233:7-12.
4. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989;9:193-7.
5. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. CAP practice parameter. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class Mike gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
7. Crosby WH. Hemochromatosis: current concepts and management. Hosp Pract 1987;22:173-7, 181-92.
8. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis: clinical manifestation. Ann Intern Med 1980;93:519-25.
9. Bulaj ZJ. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-1805.
10. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. J Med Screen 1996;3:171-177.
11. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: unifying analysis of published intervention trials. J Med Screen 1996:178-184.
12. LeSage G, Baldus WP, Fairbanks VF. Hemochromatosis: genetic or alcohol-induced? Gastroenterology 1983;84:1471-7.
13. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
14. Adams PC, Speechley M, Kertesz AE. Long-term survival in hereditary hemochromatosis. Gastroenterology 1991;101:368-72.
15. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.
16. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem 1994;40:163-6.
17. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-14.
18. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995;273:1032-8.
19. Barton JC, Edwards CQ, Bertoli LF, Shroyer TW, Hudson SL. Iron overload in African Americans. Am J Med 1995;99:616-23.
20. Berwick DM. Harvesting knowledge from improvement. JAMA 1996;275:877-8.
21. Witte DL. Measuring outcomes, why now? Clin Chem 1995;41:775-80.
22. Skikne BS, Cook JD. Screening test for iron overload. Am J Clin Nutr 1987;46:840-3.
23. Witte DL, VanNess S, Angstadt DS. Unsaturated iron binding capacity (UIBC) identifies iron overload in ambulatory individuals [Abstract]. Clin Chem 1995;41:S145.
24. Witte PL, Angstadt DS, VanNess S. What is the appropriate reference range for serum ferritin? [Abstract]. Clin Chem 1994; 40:1017.
25. Chuong JJH. A screening primer: basic principles, criteria, and pitfalls of screening with comments on colorectal carcinoma. J Clin Gastroenterol 1983;5:229-33.
26. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Boston: Little Brown, 1991.